Angion announces plans for $34.5 million initial public offering

Aegis Capital to act as underwriter

By Angela McDaniels

Tacoma, Wash., April 14 - Angion Biomedica Corp. expects to sell $34.5 million of common stock in its initial public offering, according to an S-1 filing with the Securities and Exchange Commission.

Aegis Capital Corp. is the underwriter and will be given an over-allotment option.

The company has applied to list its stock on the Nasdaq Capital Market under the symbol "ANGN."

Proceeds will be used for drug development, clinical trials, general corporate purposes, general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of intellectual property.

Angion is a clinical-stage biopharmaceutical company based in Uniondale, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.